The founder said that 50% of enrolled patients in the Phase 3 bladder cancer study reached an evaluable efficacy endpoint, ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

A growing body of research seeks to validate ctDNA as a means of guiding MIBC treatment, particularly immunotherapy.

Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrence AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global ...

New research indicates that about one-quarter of patients with bladder cancer treated with radical surgery on curative intent have detectable levels of tumour cells circulating in their blood. The ...

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a ...

Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...

Bladder cancer signs and symptoms can vary from person to person. The most common symptom is blood in the urine, also called hematuria. While this can turn the urine into a red or rusty color, it may ...